Clinical Report: How Harrow Brought Triesence Back to Market

Overview

Harrow successfully relaunched Triesence, an injectable corticosteroid, after a prolonged shortage that lasted over two years. The company reestablished the supply chain and manufacturing processes to meet current FDA standards, ensuring the product's availability for retina surgeons.

Background

Triesence (triamcinolone acetonide injectable suspension) is crucial for treating ocular inflammatory conditions and for intraoperative visualization during vitrectomy. Its absence due to supply chain issues significantly impacted both experienced and younger surgeons, who had to resort to less ideal alternatives. The restoration of Triesence is vital for maintaining effective treatment options in ophthalmic care.

Data Highlights

No numerical data available in the source material.

Key Findings

• Triesence was unavailable in the U.S. for over two years due to supply chain disruptions.
• Harrow acquired the U.S. commercial rights to Triesence in January 2023.
• The product was relaunched in October 2024 after meeting updated FDA manufacturing standards.
• Harrow implemented modern testing methods to ensure the product's quality and compliance.
• The formulation of Triesence remains unchanged, but manufacturing processes were updated to meet current standards.

Clinical Implications

The reintroduction of Triesence provides retina surgeons with a reliable treatment option for ocular inflammatory conditions and enhances intraoperative visualization. Clinicians should be aware of the product's availability and the importance of proper reimbursement support for its use in practice.

Conclusion

The successful relaunch of Triesence marks a significant advancement in ophthalmic care, restoring access to a critical medication for both treatment and surgical procedures. Ongoing support and education will be essential for integrating Triesence back into clinical practice.

References

1. Harrow Provides Triesence Relaunch Update, Ophthalmology Management, 2024 -- Full production of Triesence may be restarting later this year after 5 years on the FDA Drug Shortage list.
2. Harrow Relaunches Triesence, Retinal Physician, 2024 -- After 2 years unavailable in the US, the corticosteroid is once again on the market.
3. Dr. Amir H. Shojaei, Ophthalmology Management, 2025 -- Industry Insider provides an update on Vevye and discusses the Vevye Access for All initiative.
4. Ophthalmology Management — Dr. Amir H. Shojaei
5. Full prescribing information for TRIESENCE suspension
6. Diabetic Retinopathy Preferred Practice Pattern® - PubMed
7. A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Focal/Grid Photocoagulation for Diabetic Macular Edema - PMC